由于COVID-19疫苗接种而导致的二次血小板缩:副作用还是巧合?
Simin Khan1, Muhammed Noman Rehmani1, Ahmad Kasabali1
1Internal Medicine, Louisiana State University Health Shreveport, Shreveport, USA.
Cureus
|May 30, 2023
概括
一个罕见的严重血小板缩病例发生在一个66岁的老人中,后者接受了瑞-生物科技COVID-19疫苗增剂. 及时治疗导致血小板数量的改善,突出了疫苗副作用意识.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 广泛的COVID-19疫苗接种对于控制流行病至关重要.
- 疫苗虽然通常是安全的,但可能会导致罕见的全身副作用.
- 了解这些罕见的不良事件对于公共健康至关重要.
研究的目的:
- 在接种瑞-生物科技COVID-19疫苗后,报告一种异常的严重血小板缩病例.
- 强调识别和管理罕见的疫苗相关副作用的重要性.
- 为了解疫苗接种后可能出现的系统性不良事件做出贡献.
主要方法:
- 一个66岁的女性患者的案例研究,先前患有Sjogren综合征和C型肝炎.
- 临床表现包括渐进式疲劳,表,伤,斑点和紫外线.
- 实验室发现,在接收COVID-19疫苗增剂后三周,严重的血小板缺血 (血小板数量14000/μL).
主要成果:
- 患者接受了静脉注射免疫球蛋白和脉冲剂量普德尼松的治疗.
- 在治疗后,她的血小板数量改善到42,000/μL.
- 患者的症状消失了,她得到了出院.
结论:
- 尽管COVID-19疫苗是有效的,但很少会导致严重的血小板缺血等全身副作用.
- 医疗保健提供者应保持对此类不良事件的高度怀疑指数.
- 报告这些罕见病例对于进一步收集数据和解释疫苗安全概况至关重要.
相关概念视频
Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
17
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
17
Blood Transfusion and Agglutination
10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
Venous Thrombosis III: Interprofessional Care
12
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
12
Anticoagulant Drugs: Low-Molecular-Weight Heparins
773
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
773


